Effect of Clinical Complete Remission Following Neoadjuvant Pembrolizumab or Chemotherapy in Bladder-Preservation Strategy in Patients with Muscle-Invasive Bladder Cancer Declining Definitive Local Therapy.

Cancers (Basel) · 2024 · PMC10930778 · PMID 38473256

Europe PMC DOI

hedged sentences

0.0780

closest p · 1.6× alpha

0.2600

boldest claim

The sentences

showed a trendp = 0.078so close (0.05 < p ≤ 0.1)

Patients in the pembrolizumab group showed a trend toward longer PFS (median not reached vs. 20.2 months, p = 0.078; see Figure 2 A) and OS (median not reached vs. 26.8 months, p = 0.027; see Figure 2 B) compared to patients in the chemotherapy group.

also in 53,322 other papers

did not reach statistical significancep = 0.26not close (p > 0.1)

However, this difference did not reach statistical significance ( p = 0.26).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.